


Patent Application
Attorney Docket No. PC11053AMAG

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1X. (currently amended) A compound of Formula I



~~a prodrug of said compound,~~ or a pharmaceutically acceptable salt of said compound ~~or prodrug;~~

wherein R₁ is a) -(C₁-C₆)alkyl optionally substituted with -CF₃, b) -C≡C-CH₃, c) -C≡C-Cl, d) -C≡C-CF₃, e) -CH₂O(C₁-C₄)alkyl optionally substituted with -CF₃ or f) -CF₃;

R₂ is a) -(C₁-C₅)alkyl, b) -(C₂-C₅)alkenyl or c) -phenyl optionally substituted with one of the following: -OH, -NR₉-C(O)-(C₂-C₄)alkyl, -CN, -Z-het, -O-(C₁-C₃)alkyl-C(O)-NR₉R₁₀, -NR₉-Z-C(O)-NR₉R₁₀, -Z-NR₉-SO₂-R₁₀, -NR₉-SO₂-het, -O-C(O)-(C₁-C₄)alkyl or -O-SO₂-(C₁-C₄)alkyl;

Z for each occurrence is independently -(C₀-C₄)alkyl;

R₃ is a) -hydrogen, b) -(C₁-C₆)alkyl optionally substituted with one to three halo, c) -(C₂-C₆)alkenyl or d) -(C₂-C₆)alkynyl optionally substituted with one to three halo;

R₄ is a) -hydrogen, ~~or~~ b) -(C₂-C₅)alkyl-NR₅R₆ ~~or c) -(C₀-C₅)alkyl het;~~
~~or R₃ and R₄ are taken together with N to form het;~~

R₅ and R₆ are each independently a) hydrogen or b) -(C₁-C₃)alkyl;

het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with one to four R₇; provided that het is other than pyridinyl, imidazolyl or tetrazolyl;

Patent Application
Attorney Docket No. PC11053AMAG

R_7 is a) $-(C_1-C_6)\text{alkyl}$ optionally substituted with one to three R_8 , b) $-Z-NR_9R_{10}$ or c) $-Z-C(O)-NR_9R_{10}$;

R_8 for each occurrence is independently a) halo, b) $-OH$, c) oxo or d) $-O(C_1-C_6)\text{alkyl}$;

R_9 and R_{10} for each occurrence are independently a) $-H$ or b) $-(C_1-C_3)\text{alkyl}$;

or R_9 and R_{10} are taken together with N to form het;

provided that:

1) when R_1 is $-C\equiv C-CH_3$, R_2 is phenyl and R_3 is hydrogen, then R_4 is other than $-(CH_2)_2-N(CH_3)_2$, or $-(CH_2)_3-N(CH_3)_2$, ~~$-(CH_2)_2$ -pyrrolidinyl optionally substituted with methyl, $-(CH_2)_3$ -pyrrolidinyl or $-(CH_2)_2$ -morpholinyl;~~


2) when R_1 is ~~$-C\equiv C-CH_3$~~ , R_2 is ~~$-CH_2-CH=CH_2$~~ and R_3 is hydrogen, then R_4 is other than ~~$-(CH_2)_2$ -pyrrolidinyl;~~

2) 3) when R_1 is $-C\equiv C-CH_3$, R_2 is propyl and R_3 is hydrogen, then R_4 is other than $-(CH_2)_2-N(CH_3)_2$ or ~~$-(CH_2)_2$ -pyrrolidinyl;~~ and

3) 4) when R_1 is $-C\equiv C-CH_3$, R_2 is butyl and R_3 is hydrogen, then R_4 is other than $-(CH_2)_2-N(CH_3)_2$, ~~$-(CH_2)_2$ -pyrrolidinyl or $-(CH_2)_2$ -morpholinyl;~~ and

5) when R_1 is ~~$-C\equiv C-CH_3$~~ , R_2 is pentyl and R_3 is hydrogen, then R_4 is other than ~~$-(CH_2)_2$ -morpholinyl or $-(CH_2)_2$ -pyrrolidinyl.~~

2. (currently amended) A compound of claim 1 of Formula II



II

~~a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug;~~

wherein R_1 is a) $-(C_1-C_6)\text{alkyl}$ optionally substituted with $-CF_3$, b) $-C\equiv C-CH_3$, c) $-CF_3$ or d) $-CH_2O(C_2-C_4)\text{alkyl}$.

3. (original) A compound of claim 2 wherein R_1 is a) $-CH_2CH_2CH_3$, b) $-C\equiv C-CH_3$ or c) $-CF_3$.

Patent Application
Attorney Docket No. PC11053AMAG

4. (original) A compound of claim 3

wherein R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

5. (original) A compound of claim 4

wherein R_3 is a) methyl, b) ethyl, c) propyl or d) isopropyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

6. (original) A compound of claim 5

wherein R_3 is a) methyl or b) ethyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each methyl.

7-11. (canceled).

12. (original) A compound of claim 1

wherein R_1 is a) $-\text{CH}_2\text{CH}_2\text{CH}_3$, b) $-\text{C}\equiv\text{C}-\text{CH}_3$ or c) $-\text{CF}_3$;

R_2 is a) $-(C_1-C_5)\text{alkyl}$ or b) $-(C_2-C_5)\text{alkenyl}$;

R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is $-(C_2-C_3)\text{alkyl}-NR_5R_6$;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

13. (original) A compound of claim 12

wherein R_2 is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

R_3 is a) hydrogen, b) methyl or c) ethyl,

R_5 and R_6 are each independently a) methyl or b) ethyl.

14-17. (canceled).

18. (original) A compound of claim 1 wherein in Formula I $-\text{CH}_2-\text{R}_2$ is ethenyl or ethynyl.

19. (original) A compound of claim 4 selected from the group consisting of:

carbamic acid, [2-(dimethylamino)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;
carbamic acid, [3-(dimethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and
carbamic acid, [3-(diethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-

Patent Application
Attorney Docket No. PC11053AMAG

octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

1) ~~20~~ (original) A compound of claim 6 selected from the group consisting of:

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and

carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

21-23. (canceled).

A1 1) ~~24~~ (original) A compound of claim 13 selected from the group consisting of:

carbamic acid, (3-dimethylaminopropyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)ethyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester; and

carbamic acid, (2-dimethylaminoethyl)-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester.

25-26. (canceled)

1) ~~27~~ (currently amended) A method for the treatment of a glucocorticoid receptor-mediated disease or condition which is selected from obesity, diabetes, depression, anxiety and neurodegeneration in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, ~~a prodrug thereof~~, or a pharmaceutically acceptable salt of said compound ~~or prodrug~~.

28. (canceled)

1) ~~29~~ (currently amended) The method of claim ~~28~~ 27 wherein the condition is obesity.

30-41. (canceled)